An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for easier access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view compounded peptide therapies, which have drawn increasing interest from consumers seeking alternatives to conventional drugs. Scientists say peptide treatments could alter approaches to stubborn infections, though concerns about consistency persist. The committee's endorsement of six peptides opens the door for more widespread prescribing, even as skeptics warn of short-term evidence. Industry analysts note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on certain peptide candidates.